scispace - formally typeset
G

Giorgio Derchi

Researcher at Ente Ospedaliero Ospedali Galliera

Publications -  23
Citations -  607

Giorgio Derchi is an academic researcher from Ente Ospedaliero Ospedali Galliera. The author has contributed to research in topics: Thalassemia & Pulmonary hypertension. The author has an hindex of 10, co-authored 21 publications receiving 525 citations.

Papers
More filters
Journal ArticleDOI

Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies

TL;DR: Data indicate that sildenafil citrate is effective in the treatment of PH in hemoglobinopathies that cannot be treated with alternative oral drugs and is well tolerated long-term at a daily dose of 100 mg, though studies including more patients may uncover toxicities and limitations of efficacy.
Journal ArticleDOI

Prevalence and Risk Factors for Pulmonary Arterial Hypertension in a Large Group of β-Thalassemia Patients Using Right Heart Catheterization A Webthal Study

TL;DR: A multicenter cross-sectional study of 1309 Italian β-thalassemia patients with tricuspid-valve regurgitant jet velocity ≥ 32 m/s on transthoracic echocardiography further underwent right heart catheterization to confirm the diagnosis of pulmonary arterial hypertension.
Journal ArticleDOI

Guideline recommendations for heart complications in thalassemia major.

TL;DR: These recommendations outline the definition, the follow-up and the treatment of the main heart complications in this group of patients and perform according to the American Cardiology College (ACC) and American Heart Association (AHA) guidelines.
Journal ArticleDOI

Myocardial scarring by delayed enhancement cardiovascular magnetic resonance in thalassaemia major

TL;DR: In patients with thalassaemia the significant presence of myocardial fibrosis/necrosis seems to be a time-dependent process correlating with cardiovascular risk factors and cardiac complications.
Journal ArticleDOI

Long-term treatment with oral sildenafil in a thalassemic patient with pulmonary hypertension

TL;DR: Pulmonary hypertension (PHT), defined as Doppler peak systolic tricuspid gradient (TG) higher than 30 mmHg, develops in a high percentage of patients with β-thalassemia (10% in thalassemia major and greater than 50% in THA intermedia [TI]).